Prenetics Ends Bitcoin Treasury Strategy Amid Crypto Winter Fears

Source: CryptoTale Original Title: Prenetics Ends Bitcoin Treasury Strategy Amid Crypto Winter Fears Original Link:

Overview

Prenetics, a Nasdaq-listed health sciences company, has ended its Bitcoin treasury accumulation strategy as prolonged weakness in digital-asset markets reshapes corporate risk decisions. The company confirmed that it stopped purchasing Bitcoin on Dec. 4 and will redirect capital and management focus toward its consumer wellness business, IM8.

The decision places Prenetics among a growing group of firms reassessing exposure to crypto assets as volatility persists and price momentum remains uneven. While the company will retain its existing Bitcoin holdings, it will no longer allocate new funds toward digital-asset accumulation.

A Shift Back to Core Operations

The strategic pivot centers on IM8, a nutritional supplement brand co-founded by English football icon David Beckham, who is also a strategic investor in Prenetics. IM8 has become the fastest-growing supplement brand in industry history, reaching more than $100 million in annualized recurring revenue within 11 months of launch.

Management said the decision allows Prenetics to deploy resources toward what it views as a clearer and more immediate growth opportunity. The consumer wellness segment has shown consistent demand despite broader economic pressures, offering revenue visibility that contrasts with the swings seen in crypto markets.

Prenetics stated that its financial position remains strong. The balance sheet includes over $70 million in cash and cash equivalents, 510 BTC valued at nearly $45 million at recent prices, and no outstanding debt. The company said this structure provides flexibility while it focuses on scaling IM8 globally.

From Crypto Treasury to Caution

When Prenetics entered the Bitcoin treasury space in mid-2025, it stood out. Healthcare companies rarely dip into digital-asset reserves, and the firm’s disclosure of a roughly $20 million purchase, 187.42 BTC, signaled a willingness to experiment with treasury diversification.

Executives at the time described the strategy as a disciplined allocation rather than a speculative chase. However, Bitcoin slipped into a jagged cycle of rallies that failed to hold, followed by retracements that accelerated faster than many corporate holders preferred.

Those swings made the treasury conversation more complicated inside the firm. A strategy that sounded balanced in June felt increasingly exposed by autumn. By late year, the board sided with caution. The view was straightforward: invest where the company has clearer visibility and higher odds of compounding returns.

CEO Danny Yeung said IM8’s early performance moved faster than expected and warranted a sharper strategic tilt. He added that the company’s decision reflects a disciplined capital strategy aimed at long-term shareholder value.

Bitcoin Technical Structure Signals Market Fatigue

Bitcoin’s chart offered little comfort to institutions reviewing treasury policies. After hitting an all-time high around $126K on Oct. 6, the asset unwound quickly. The slide, about 18% in just four days, dragged prices toward $100K, a level not seen since late June. A modest rebound lifted Bitcoin back above $116K, though it barely lasted.

Sellers returned with even more force, sending the market down nearly 30% and pushing prices toward an eight-month low of around $80K. The broader picture shows a market losing momentum. On higher timeframes, Bitcoin has settled into a tightening symmetrical triangle, a pattern that usually reflects indecision rather than strength.

Volatility has also thinned. From a broader look, though, the formation tilts more bearish, echoing the kind of pennant structures that often follow sharp down moves. Meanwhile, momentum readings tell a similar story. The Relative Strength Index sits near 48, a middle zone that rarely signals much.

It doesn’t confirm a bottom, nor does it suggest aggressive accumulation. It simply aligns with a market catching its breath, or perhaps searching for direction while major holders reassess their risk tolerance. For Prenetics, that backdrop made the decision easier.